At a glance
ClinicalIndex Comparison Record- ✓Age 12 months or younger
- ✓Diagnosis of obstructive sleep apnea confirmed by prior polysomnography
- ✕Central apneas comprising >50% of the apnea-hypopnea index on previous PSG
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen (O2) as a Treatment for Obstructive Sleep Apnea (OSA) in Infants
In Brief
A clinical study evaluating HFNC and Low flow oxygen by nasal cannula for Obstructive Sleep Apnea. Completed, enrolled 9 participants across 2 sites.
Detailed Summary
This is a small pilot study that will compare High Flow Nasal Cannula (HFNC) therapy to oxygen nasal cannula therapy on infants who have obstructive sleep apnea (OSA) and are scheduled for a clinically ordered sleep study called polysomnography (PSG). The HFNC procedure uses humidified room air delivered by nasal cannula at higher pressures and will test if HFNC can control OSA in infants better or as well as low flow nasal oxygen, the current clinical standard of care. All the infants in the study will have a brief test period of about 3 to 4 hours with the HFNC before participants begin their standard clinical PSG for titration of oxygen by nasal cannula for treatment of OSA.
Study Details
Timeline
Interventions
All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea